港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

瑞博生物-B

70.050

-4.000-5.40%

成交量：20.10万

成交额：1,436.39万

市值：119.47亿

市盈率：-37.76

高：74.550

开：74.050

低：69.050

收：74.050

52周最高：95.800

52周最低：58.550

股本：1.71亿

香港流通股本：1.71亿

量比：0.52

换手率：0.12%

股息：- -

股息率：- -

每股收益(LYR):-1.855

净资产收益率：--

总资产收益率：--

市净率：-180.60

市盈率(LYR):-37.76

市销率: 58.58

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

追求乙肝功能性治愈！国内 7 家企业进展迅速，最快已 III 期

2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高

近 60 亿美元！不到十天两起小核酸授权出海

瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/06938"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06938","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","market":"HK","secType":"STK","nameCN":"瑞博生物-B","latestPrice":70.05,"timestamp":1770970087275,"preClose":74.05,"halted":0,"volume":201000,"delay":0,"changeRate":-0.05401755570560433,"floatShares":170554910,"shares":170554910,"eps":-1.855,"marketStatus":"未开盘","change":-4,"latestTime":"02-13 16:08:07","open":74.05,"high":74.55,"low":69.05,"amount":14363887,"amplitude":0.074274,"askPrice":70.5,"askSize":400,"bidPrice":70.05,"bidSize":9800,"shortable":0,"etf":0,"ttmEps":-1.502,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1771205400000},"marketStatusCode":0,"adr":0,"listingDate":1767888000000,"exchange":"SEHK","adjPreClose":74.05,"openAndCloseTimeList":[[1770946200000,1770955200000],[1770958800000,1770969600000]],"volumeRatio":0.5237602126454081,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06938\",,,,,undefined,":{"symbol":"06938","floatShares":170554910,"roa":"--","roe":"--","lyrEps":-1.855,"volumeRatio":0.5237602126454081,"shares":170554910,"dividePrice":0,"high":74.55,"amplitude":0.074274,"preClose":74.05,"low":69.05,"week52Low":58.55,"pbRate":"-180.60","psRate":"58.58","week52High":95.8,"institutionHeld":0,"latestPrice":70.05,"committee":0.921569,"eps":-1.855,"divideRate":0,"volume":201000,"delay":0,"ttmEps":-1.502,"open":74.05,"prevYearClose":57.97,"prevWeekClose":70.05,"prevMonthClose":68.8,"prevQuarterClose":57.97,"fiveDayClose":69.3,"twentyDayClose":75.8,"sixtyDayClose":57.97},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06938\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06938\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06938\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06938\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06938","date":"2026-02-13","current":-46.637816,"percent":1,"low":-50.513246,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"high":-47.784644,"avg":-49.148945,"sd":1.364301,"marketCap":11947371445},"quantilePoints":[{"date":"2026-02-13","current":-47.784644,"twenty":-49.967526,"median":-49.148945,"eighty":-48.330365,"marketCap":11947371445}],"updateTime":1771198768532},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06938\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2611140454","title":"追求乙肝功能性治愈 ！国内 7 家企业进展迅速，最快已 III 期","url":"https://stock-news.laohu8.com/highlight/detail?id=2611140454","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611140454?lang=zh_cn&edition=fundamental","pubTime":"2026-02-15 07:20","pubTimestamp":1771111229,"startTime":"0","endTime":"0","summary":"当下，追求功能性治愈已成为全球慢性乙肝治疗领域的核心趋势，国内创新药企也紧跟这一方向积极布局，以 ASO 和 siRNA 为主，还包含了细胞疗法、治疗性疫苗等。同月，AHB-137 的 III 期 AUSHINE 临床研究已顺利完成患者入组。2025 年 9 月，该产品被 CDE 纳入拟突破性治疗品种公示名单。另外，腾盛博药将在 2026 年公布两项额外的 IIb 期研究数据。2025 年 9 月，BW-20507 已经完成 II 期临床试验首例患者给药。其 II 期临床试验已经获得批准。目前，正大天晴正在开展 TQA3038 的 Ib/IIa 期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260215073412a4a5af8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1167","06938","01611","02137","BK1612"],"gpt_icon":0},{"id":"2611165746","title":"2026年中国生物科技授权交易将迎爆发式增长，有望创历史新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165746","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165746?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 17:05","pubTimestamp":1770973500,"startTime":"0","endTime":"0","summary":"全球制药企业在专利到期前纷纷削减成本，正加大力度寻找中国研发的创新候选药物，行业分析师预计，今年相关授权交易规模将飙升至历史新高。2026 年至今已宣布38 笔对外授权交易；2025 年全年为186 笔。行业咨询机构 Vision Lifesciences 在 2026 年生物科技授权展望中称，中国在抗体药物偶联物领域全球领先，相关授权交易占全球近90%。首付款大幅上涨随着交易规模扩大，全球药企获取中国药物开发权所需支付的首付款也大幅飙升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260213182820a6f7567b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","01093","BK1161"],"gpt_icon":0},{"id":"2611165798","title":"近 60 亿美元！不到十天两起小核酸授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2611165798","media":"医麦客","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611165798?lang=zh_cn&edition=fundamental","pubTime":"2026-02-13 07:20","pubTimestamp":1770938451,"startTime":"0","endTime":"0","summary":"根据协议条款，瑞博生物将授予 Madrigal 多款 MASH 领域单靶点及双靶点临床前 siRNA 资产的全球独家研发、生产与商业化权利。Madrigal 的 THR-β 激动剂已经获批上市，用于治疗 MASH，2025 年前三季度销售额 6.4 亿美元，预计全年超过 10 亿美元。这是瑞博生物肝靶向 RiboGalSTAR 平台第二次达成重磅出海合作。早在 2023 年，瑞博生物就此平台与勃林格殷格翰达成共同开发治疗 MASH 的小核酸创新疗法的合作，合作总额超 20 亿美元，成为国内首个向 MNC 许可的 RNAi 技术平台。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021307240697a5ffdf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06938","BK1161"],"gpt_icon":0},{"id":"2610915655","title":"瑞博生物-B(06938)因悉数行使超额配股权发行474.14万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2610915655","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610915655?lang=zh_cn&edition=fundamental","pubTime":"2026-02-12 14:11","pubTimestamp":1770876660,"startTime":"0","endTime":"0","summary":"智通财经APP讯，瑞博生物-B(06938)发布公告，于2026年2月10日根据悉数行使超额配股权而发行及配发474.14万股H股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06938","BK1161"],"gpt_icon":0}],"pageSize":4,"totalPage":20,"pageCount":1,"totalSize":78,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/06938\",params:#limit:6,delay:false,,,undefined,":[]}}